tradingkey.logo
tradingkey.logo
Search

Journey Medical Corp

DERM
Add to Watchlist
6.542USD
-0.108-1.62%
Market hours ETQuotes delayed by 15 min
177.59MMarket Cap
LossP/E TTM

Forecast

Currency: USD Updated: 2026-08-13
Previous score
8.00
Change
0
The current earnings forecast score of Journey Medical Corp is 8.00, ranking 59 out of 156 in the Pharmaceuticals industry. The average price target is 13.00, with a high of 16.00 and a low of 12.00.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
13.500
Target Price
+109.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Journey Medical Corp
DERM
4
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Regeneron Pharmaceuticals Inc
REGN
32
1
2
3
...
32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

FAQs

What is Journey Medical Corp's expected revenue for the next quarter?

Journey Medical Corp's expected revenue is 22.40M.

What is Journey Medical Corp's price target?

Analysts forecast that Journey Medical Corp's price target is USD 13.00, with the highest forecast at USD 16.00 and the lowest forecast at USD 12.00.

How have Journey Medical CorpDERM's recent earnings per share performed?

The market expectation was USD -0.01, while Journey Medical CorpDERM's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD 0.05.

What is the analyst rating for Journey Medical Corp?

Based on the ratings of Journey Medical Corp's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.